MedTrace Logo

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

NCT07156201 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-11-26

No results posted yet for this study

Summary

This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants.

Conditions

  • KCNT1-Related Epilepsy

Interventions

DRUG

ABS-1230

ABS-1230

DRUG

Placebo

Placebo

DRUG

Omeprazole

Omeprazole

Sponsors & Collaborators

  • Actio Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Actio Bioscences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-28
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07156201 on ClinicalTrials.gov